Oncopharmpod
Tarlatamab
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:10:12
- More information
Informações:
Synopsis
A new drug for small-cell lung cancer, a bispecific, targeting DLL3 on small-cell lung cancer and CD3 on T-cells is FDA approved. But, infigratinib's FDA approval for cholangiocarcinoma is withdrawn.
